Treatment of choreoathetotic movements in chronic liver disease with a dopamine-blocking agent. Pathophysiologic implications.
D000368:Aged; D001479:Basal Ganglia / Q000378:metabolism; D001927:Brain Diseases / Q000209:etiology*; D002819:Chorea / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D004562:Electrocardiography; D004569:Electroencephalography; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D008297:Male; D010648:Phenylacetates / Q000134:cerebrospinal fluid; D011167:Portacaval Shunt, Surgical / Q000009:adverse effects*; D009435:Synaptic Transmission
D010648:Phenylacetates; D006220:Haloperidol; D004298:Dopamine